Jeroen Bakker, PhD, is a Partner at Novo Holdings Seed Investments. He has over a decade of biotech investment experience, driving investment processes and portfolio management for companies like Adcendo, Antag Therapeutics and Rappta Therapeutics (licensed to Springworks Therapeutics). He’s currently driving Novo Holdings new €188m investment strategy around quantum which aims to invest in companies and funds that are utilizing quantum tech to impact human and planetary health.

Prior to joining Novo Seeds, Jeroen was an Associate at M Ventures, the corporate venture capital arm of Merck, where he was responsible for sourcing, due diligence and gained board exposure for a variety of Seed and Series A investments across Europe, United States Israel. Jeroen also received operational experience through a number of roles in Syntaxin (acquired by Ipsen), Inthera and ISD Immunotech. Prior to joining biotech, he was a Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego.

Jeroen holds a PhD in Immunology from the University of Amsterdam, a MSc in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship and a BSc from the Technical University of Delft. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology, served on the board of BiOrigin, a Novo Holdings-backed entrepreneur-in-residence subsidiary and a member of REBBLS, a Danish networking organization focusing on young biotech entrepreneurs.